Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
Mar 1, 2022
1 min read
Updated: Sep 13, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.
As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.
El concepto de Magis TV gratis puede despertar bastante interés, aunque conviene analizar cuidadosamente cualquier información encontrada. No todas las páginas ofrecen datos fiables o actualizados, por lo que revisar la fuente, las condiciones y la seguridad resulta esencial antes de confiar en una determinada alternativa.
Preparing for parenthood through adoption can involve learning about attachment, trauma, child development, communication, and positive discipline. These topics can help prospective parents understand how a child’s previous experiences may influence behavior and emotional responses. Parenting education can encourage patience and flexibility rather than relying on assumptions. Families who understand https://www.adopthelp.com/ developmental needs may feel better prepared to respond to challenges constructively. Continued learning after placement can also help parents adapt as children grow and their needs change.
The IL-12 effort sounds like an important milestone, especially given the challenges of translating promising immunology research into meaningful clinical progress. It will be interesting to see how Rupert Vessey and the broader team build on this partnership and define the next stage of development. For readers who enjoy a quick mental challenge between biotech updates, I’ve also been playing Poople Answer, a free word-ladder game with unlimited rounds and no daily waiting.
The progress on the IL-12 program is encouraging, especially with a strong partner helping move the effort forward. It will be interesting to see how Rupert Vessey shapes the next stage and whether the data can translate into meaningful clinical benefits. Biotech development often involves navigating uncertainty, much like identifying an unfamiliar place from limited clues. For readers who enjoy that kind of challenge in a different setting, free world guesser offers unlimited location-based rounds without requiring sign-up.
Interesting update on the IL-12 effort—the partner’s progress seems to give Bristol Myers a meaningful boost, while Rupert Vessey now faces the challenge of turning that momentum into a durable development strategy. I’m curious to see how this work fits into the broader pipeline and what milestones come next. After reading such a dense biotech update, I took a quick break with the browser-based PolyTrack game, which has community-built tracks and requires no download.